Table 2 Correlation of Cezanne protein expression with clinicopathological parameters
Characteristics | No. of patients | Cezanne expression (%) | P -value | |
|---|---|---|---|---|
Low | High | |||
Gender | ||||
Female | 26 | 10 (38.5%) | 16 (61.5%) | 0.103 |
Male | 204 | 113 (55.4%) | 91 (44.6%) | |
Age (years) | ||||
≤50 | 118 | 62 (52.5%) | 56 (47.5%) | 0.826 |
>50 | 112 | 61 (54.5%) | 52 (45.5%) | |
AFP (μg/l) | ||||
≤20 | 82 | 44 (53.7%) | 38 (46.3%) | 0.967 |
>20 | 148 | 79 (53.4%) | 69 (46.6%) | |
HBsAg | ||||
Negative | 15 | 9 (60.0%) | 6 (40.0%) | 0.600 |
Positive | 215 | 114 (53.0%) | 101 (47.0%) | |
GGT (U/l) | ||||
≤50 | 122 | 58 (47.5%) | 64 (52.5%) | 0.055 |
>50 | 108 | 65 (60.2%) | 43 (39.8%) | |
Liver cirrhosis | ||||
No | 50 | 26 (52.0%) | 24 (48.0%) | 0.813 |
Yes | 180 | 97 (53.9%) | 83 (46.1%) | |
Tumor size (cm) | ||||
≤5 | 132 | 58 (43.9%) | 74 (56.1%) | 0.001 |
>5 | 98 | 65 (66.3%) | 33 (33.7%) | |
Tumor number* | ||||
Single | 213 | 113 (53.1%) | 100 (46.9%) | 0.646 |
Multiple | 17 | 10 (58.8%) | 7 (41.2%) | |
Satellite nodule | ||||
No | 199 | 98 (49.2%) | 101 (50.8%) | 0.001 |
Yes | 31 | 25 (80.6%) | 6 (19.4%) | |
Tumor capsule | ||||
No/incomplete | 141 | 77 (54.6%) | 64 (45.4%) | 0.665 |
Complete | 89 | 46 (51.7%) | 43 (48.3%) | |
Tumor differentiation | ||||
I-II | 157 | 88 (56.1%) | 69 (43.9%) | 0.251 |
III-IV | 73 | 35 (47.9%) | 38 (52.1%) | |
Vascular invasion | ||||
No | 207 | 105 (50.7%) | 102 (49.3%) | 0.012 |
Yes | 23 | 18 (78.3%) | 5 (21.7%) | |
TNM stage | ||||
I | 178 | 88 (49.4%) | 90 (50.6%) | 0.020 |
II | 11 | 5 (45.5%) | 6 (54.5%) | |
III | 41 | 30 (73.2%) | 11 (26.8%) | |
BCLC stage | ||||
0 | 20 | 4 (20.0%) | 16 (80.0%) | 0.001 |
A | 106 | 52 (49.1%) | 54 (50.9%) | |
B | 80 | 49 (61.3%) | 31 (38.7%) | |
C | 24 | 18 (75.0%) | 6 (25.0%) | |
Early recurrence | ||||
No | 145 | 56 (38.6%) | 89 (61.4%) | <0.001 |
Yes | 85 | 67 (78.8%) | 18 (21.2%) | |
MMP-9 expression | ||||
Low | 118 | 51 (43.2%) | 67 (56.8%) | 0.001 |
High | 112 | 72 (64.3%) | 40 (35.7%) | |